Performance Features of 2 µm Superficially Porous Particle Columns

Timothy J. Langlois, Joseph J. DeStefano, Barry E. Boyes, Stephanie A. Schuster, William L. Miles and Joseph J. Kirkland Advanced Materials Technology, Inc., 3521 Silverside Rd., Wilmington, DE 19810

Presented at HPLC 2015, Geneva

Introduction

Superficially porous particles (SPP) in the 2.5 - 2.7 µm range provide nearly the same efficiency and resolution of sub-2 µm totally porous particles (TPP), but at one-half to onethird of the operating pressure. The performance advantage of SPP over TPP shown by these $2.5 - 2.7 \mu m$ SPP has led to the introduction of smaller diameter SPP as a natural extension of this technology. The 40 to 50% efficiency advantage of SPP over TPP continues to be demonstrated as particle size is reduced to 2.0 µm. The characteristics of these 2.0 µm SPP are described and studies comparing some present sub-2 µm SPP and TPP commercial columns for efficiency and pressure are presented. High speed reversed-phase application examples include explosives, anticoagulants, and steroids. High throughput enzymatic analyses using HILIC have been applied to analysis of both crude tissue extracts and purified enzyme preparations.

An Alternative to Sub-2µm: 2µm SPP

- 2µm SPP keeps pressure within a comfort zone and retains most of advantages of sub-2µm columns
 - Higher efficiencies than sub-2µm TPP columns
 - Lower pressure than sub-2µm columns (TPP or SPP)
 - Short columns exhibit the high efficiencies wanted for fast method development
- Minimizes disadvantages of sub-2µm columns
 - Greater efficiencies than sub-2µm TPP with lower pressure requirements
 - Similar efficiencies as sub-2µm SPP with lower pressure requirements
 - Uses 1-micron frits that are less prone to plugging
 - Reduced frictional heating

HALO 2 vs. Competitor Solid-Core Sub-2µm



Explosives Separation : HALO 2 vs. Sub-2µm TPP



Ballistic Separation of Anticoagulants

Peak Capacity: 60

Column: 2.1 x 30 mm HALO 2 C18, 2µm, 90 Å

%B

20 - 75%

Mobile Phase A: 20 mM formic acid

Mobile Phase B: 50/50 ACN/MeOH

0 – 0.06

0.06 - 1.06

Time

Grac

S



Particle Size Distributions

 Flow rate: 1.1 mL/min
 Peak Identities

 Temperature: 45 °C
 1. Uracil

 Detection: 254 nm
 2. 6,7-Dihydrox

 Injection: 0.2 μL
 3. 4-Hydroxycou

 Max Pressure: 430 bar
 4. Coumarin

Uracil
 6,7-Dihydroxycoumarin
 4-Hydroxycoumarin
 Coumarin
 6-Chloro-4-hydroxycoumari
 Warfarin
 Coumatetralyl
 Coumachlor
 Peak capacity was calculated using the

 $t_{c} - t_{c}$

Rapid 2 µm Halo Penta-HILIC Analysis of Bovine Guanine Deaminase

Guanine deaminase, also variously known as "nedasin " or "cypin", catalyzes the purine catabolic commitment step from guanine, through xanthine, to the elimination product, uric acid. In mammals, the enzyme is predominantly cytoplasmic as a homodimer, with catalytic domains for the Zn+2-dependent hydrolytic deamination of guanine to xanthine plus ammonia.

- Structure: c. 50 kDa subunits with sequences that vary at internal and terminal sites, due to exon selection
 Interactions: tubulin, snapin, and post-synaptic domain protein 95 (PSD-95, via PZD binding motifs at
- the C-termini)
- Sequence variants occur mostly at the protein binding domains, although minor variants lack the catalytic site
- In mammalian brain high levels are in telencephalic brain regions, low in white matter and cerebellum
 Moderate levels in liver and certain other specialized organs
- Moderate levels in liver and certain other specialized org
 Low levels in plasma/serum: altered by liver dysfunction
- Low levels in plasma/serum; altered by liver dysfunction
 Actual role of guarance deaminase in specialized erran metabolism and synaptic p
- Actual role of guanine deaminase in specialized organ metabolism and synaptic physiology is uncertain
 Brouisuu tissue homogenete enzyme assaure are complex, using coupled enzyme/cofactor indirect reader
- Previous tissue homogenate enzyme assays are complex, using coupled enzyme/cofactor indirect readout
 Spectrophotometric high throughput assay has uncertain specificity and requires guanine as substrate near the limit of aqueous solution solubility

To measure tissue enzyme levels, follow purification processes, and assay enzyme kinetics and inhibitors, LC/UV and LC/MS methods are needed. Our assay measures deamination of guanine to xanthine, using rapid HILIC separation. Crude homogenates use 8-azaguanine as substrate due to the presence of endogenous xanthine; product 8-azaxanthine reflects enzyme activity without correction for background. HTP assay and kinetic analysis with partially purified or purified enzyme measures the direct conversion of guanine to xanthine.

Reactions Catalyzed by Guanine Deaminase



Assay Conditions and LC Analysis

- Enzymatic Reaction:
- Temp: 25 °C
- Substrate: 0.2 mM guanine (HTP) or 0.4 mM AzG (tissue)
 Buffer: 0.1 M Bicine-HCL pH 7.8
- Buffer: 0.1 M Bicine-HCl, pH 7.8
 Internal standard: 0.5 μM 1-methylguanine (tissue)
- $0.5 \ \mu\text{M}$ 7-methylguanine (HTP)
- Stop Solution: 1% HOAc/99% Acetonitrile with IS
 Workflow:
 - Incubate homogenate (10%) or purified enzyme in 10-100 µL of substrate mix
 - 9 volumes Stop Solution, ice bath 5 minutes
 - 10 minute centrifuge (16,000 x G) Direct injection of supernatant on LC
 - Direct injection of supernatant on LC

LC Conditions: 3.0 x 75 mm 2.0 µm particle HALO 2 Penta-HILIC Shimadzu Nexera with SPD-30A DAD at 270 nm (10 nm BW)

- 35 °C, 0.8 mL/min initial flow rate; 2-20 µL injection
- Eluents: A 0.1 M NH₄OAc (pH 6.5); B AcN
 During equilibration flow rate increased to 1.5 mL (mi

During equilibration, now rate increased to 1.5 r					
Gradient Profile					
	Time	Component	Action	Parameter	
	0.00				
	1.90	Pumps	Pump B Conc.	80	
	1.91	Pumps	Total Flow	0.8	
	2.10	Pumps	Total Flow	1.5	
	2.11	Pumps	Pump B Conc.	40	
	3.10	Pumps	Pump B Conc.	40	
	3.20	Pumps	Pump B Conc.	90	
	6.00	Pumps	Total Flow	1.5	
	6.20	Pumps	Total Flow	0.8	
	6.50	Controller	Stop		







A rapid separation of anticoagulants with high peak capacity in under a minute is achieved due to the high efficiency of a short HALO 2 C18 column.

Carbonyl-DNPH High Resolution Separation



The curve for HALO 2 remains flat over a wide range of linear velocities allowing operation at increased flow rate with minimal loss of efficiency.

Chromatographic Comparison: HALO 2 vs. Sub-2µm TPP





Steroids Separation: HALO 2 PFP



HALO 2 PFP has unique selectivity for the separation of closely related steroids.

Analysis time for this HILIC method is 6.5 minutes run to run, with complete re-equilibration of column

Time Course of Guanine Deamination by Partially Purified Bovine Cortex Enzyme (HTP Conditions)

25°C; 0.1M Bicine (pH 7.8); 200 μM Guanine; 4 μg protein/rx



Guanine Deaminase in Brain Tissue Homogenates



In tissue homogenates, endogenous xanthine is a significant background for the enzyme assay

Neocortex and cerebellum tissue homogenates samples exhibit endogenous X (and other unknown detected molecules)

• Use of 8-AzaG as substrate yields 8-AzaX as a product, well resolved from endogenous X and other compounds

Neocortex shows 8-AzaX formed by guanine deaminase – no significant interferences from tissues at AzX or IS elution

Cerebellum exhibits little guanine deaminase activity, as expected

Conclusions

- Sub-2µm SPP are not needed for most routine applications. In fact, they present challenges in laboratory environments, i.e. higher back pressure.
- HALO 2 columns are a good compromise of speed and efficiency with superior advantages for complex samples.
- · HILIC method permits highly selective resolution of these polar analytes.
- Highly efficient 2 µm HILIC allows rapid and selective assay of this important purine catabolic enzyme.

Acknowledgements: Robert Moran, Benjamin Libert, and William Johnson for advice and technical assistance. Supported in part by NIH Grant GM093747 (BEB).